FDA promises Roche a snap decision on Tecentriq triple for frontline lung cancer as it falls even further behind Merck, Bristol-Myers
Roche is getting some help from the FDA in its quest to start making up some of the multibillion-dollar distance that separates the global player …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
